COMPARE PEPTIDES

Compare status, evidence, and next steps.

Put up to three peptides side by side to compare what FDA has done, what has been studied in people, and what comes next.

Compound 1Compound 2Compound 3

FDA statusFDA approved?What changed legallyHuman studiesWhat comes nextUse FDA reviewed

Committee favored

BPC-157

Favorable PCAC voteAdvisory recommendation; FDA final action is still pending.

NoNo approved indication

No final legal changeNo final FDA action identified

LimitedAnimal and laboratory research shown separately

FDA actionFDA must decide whether and how to act on the committee recommendation.

Ulcerative colitisThe use FDA reviewed or expects to review

Committee favored

Favorable PCAC voteAdvisory recommendation; FDA final action is still pending.

NoNo approved indication

No final legal changeNo final FDA action identified

None identified by FDAAnimal and laboratory research shown separately

FDA actionFDA must decide whether and how to act on the committee recommendation.

Wound healingThe use FDA reviewed or expects to review

Committee did not favor

Unfavorable PCAC voteCommittee did not recommend inclusion; FDA final action is still pending.

NoNo approved indication

No final legal changeNo final FDA action identified

LimitedAnimal and laboratory research shown separately

FDA responseFDA may adopt, reject, or otherwise respond to the committee recommendation.

Opioid withdrawal, chronic insomnia, and narcolepsyThe use FDA reviewed or expects to review

THE BOTTOM LINE

These peptides are at different points in FDA review. None is FDA approved, and none has received final FDA action adding it to the 503A Bulks List.